Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Baculoviral IAP repeat-containing protein 4 (BIRC4), commonly known as X-linked inhibitor of apoptosis protein (XIAP), is a multi-functional protein that plays a central role in regulating cell death, inflammation, and immune signaling. As the most potent member of the inhibitor of apoptosis (IAP) family, BIRC4 directly binds and inhibits initiator caspase-9 and effector caspases-3 and -7 through its baculovirus IAP repeat (BIR) domains, thereby blocking both intrinsic and extrinsic apoptotic pathways. Additionally, its C-terminal RING domain possesses E3 ubiquitin ligase activity, which mediates the ubiquitination of target proteins, including caspases and RIPK2, to modulate NF-kappa-B and MAP kinase signaling pathways.
BIRC4 is frequently overexpressed in various human cancers, where it contributes to tumor cell survival, metastasis, and resistance to chemotherapy and radiation. Conversely, loss-of-function mutations in the BIRC4 gene cause X-linked lymphoproliferative syndrome type 2 (XLP-2), a rare immunodeficiency characterized by severe immune dysregulation, hemophagocytic lymphohistiocytosis (HLH), and inflammatory bowel disease. Therapeutic strategies targeting BIRC4 primarily involve small-molecule SMAC mimetics (such as xevinapant, tolinapant, and birinapant) that act as antagonists to disrupt caspase binding and promote apoptosis in cancer cells. In contrast, treatment for BIRC4 deficiency focuses on managing hyperinflammation, utilizing agents like the interleukin-18 inhibitor tadekinig alfa.
IAP antagonism (SMAC mimetics) to prevent caspase inhibition and promote apoptosis in cancer cells; antisense-mediated knockdown of XIAP mRNA; or IL-18 inhibition (e.g., with Tadekinig alfa) to manage hyperinflammation in XIAP-deficient patients.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Baculoviral IAP repeat-containing protein 4 (XIAP).